The S&P 500 Index ($SPX ) (SPY ) closed up by +0.33% on Thursday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +1.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.05%.  December E-mini S&P futures (ESZ26 ) rose +0.28%, and December E-mini...

Stocks Settle Mixed as Broader Market Recovers from Chip Stock Rout

The S&P 500 Index ($SPX ) (SPY ) is up by +0.13% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +1.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.57%.  December E-mini S&P futures (ESZ26 ) are up +0158%, and December E-mini...

Stock Indexes Rebound as Investors Rotate Out of Chip Stocks

The S&P 500 Index ($SPX ) (SPY ) is down by -0.57% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.30%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.71%.  December E-mini S&P futures (ESZ26 ) are down -0.58%, and December E-mini...

Stocks Pressured as Chipmaker Selloff Deepens

Key PointsThanks to its most recent acquisition, Vertex now has some promising products in the field of hormone disorders.

Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders

The S&P 500 Index ($SPX ) (SPY ) closed down by -1.11% on Wednesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.02%.  December E-mini S&P futures (ESZ26 ) fell -1.16%, and December E-mini...

Stocks Sharply Lower on Inflation Woes and Slumping Chipmakers

The S&P 500 Index ($SPX ) (SPY ) is down by -0.75% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.11%.  December E-mini S&P futures (ESZ26 ) are down -0.80%, and December E-mini...

Stocks and Bonds Fall on a Strong CPI Report

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Incorporated News